Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03075514
Other study ID # UoL001277
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2017
Est. completion date March 5, 2019

Study information

Verified date April 2019
Source University of Liverpool
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Glioblastoma (GB) is the commonest form of brain cancer in adults. Despite current treatment options including surgery, radiotherapy and chemotherapy, overall survival is poor. Therefore, other treatment options are being explored and there is increasing interest in the possibility of using the ketogenic diet (KD), alongside current treatment options.

The KD is a high fat, low carbohydrate diet. This encourages the body to use fat (broken down to ketones) as its primary energy source, instead of carbohydrate (broken down to glucose, a type of sugar). KDs have been considered for use in patients with GB as this type of cancer is thought to use glucose as its main energy supply, which is of short supply in this diet. Animal studies have shown KDs may make GB more responsive to radiotherapy and chemotherapy and could improve survival by slowing the cancer's growth. However, clinical studies are needed in humans to assess any possible benefits.

This trial will see patients randomly assigned to one of two types of KDs; the modified ketogenic diet (MKD) and the medium chain triglyceride ketogenic diet (MCT). Both diets follow the same high fat, low carbohydrate principles, with the MCT diet requiring the patient to take some of the fat as a supplement drink instead of as food. Patients will follow the diet for 12 weeks initially. The trial will look to enroll newly diagnosed GB patients, from The Walton Centre NHS Foundation Trust over a 12 month period.

The aim of the trial is to investigate protocol feasibility and patient impact by comparing two KDs in an NHS setting, with a view to informing future phase III clinical trials.


Description:

A prospective, non-blinded, randomized, pilot study will be undertaken in patients with glioblastoma (GB). Patients will be randomized to the modified ketogenic diet (MKD) or the medium chain triglyceride ketogenic diet (MCT) for a 12 week period (primary completion). If patients wish to remain on diet, they will be offered dietetic support for a total of 12 months (secondary completion).

The trial will be open to all Walton Centre Foundation Trust patients with a newly diagnosed GB, who have undergone surgical resection or biopsy within the last four months and who are going on to receive/ are currently receiving/ have completed oncological treatments (radiotherapy or chemotherapy or chemoradiotherapy). Patients will be referred via neuro-oncology multi-disciplinary meetings and neurosurgical clinics, post histology. The diet will be offered alongside standard care, commencing within four months of surgery.

Both diets are high in fat and low in carbohydrate, but contain different types and amounts of fats. The MKD is 80% fat (predominately long chain fatty acids) and 5% carbohydrate, whilst the MCT diet is 75% fat (30% of which is medium chain fatty acids) and 10% carbohydrate.

A permuted block randomization method will be adopted, using 'sealedenvelope' randomization system. This will be set up and administered by the statistician, who is not involved with the recruiting of patients.

Patients will receive regular input from the trial dietitian. This includes clinical consultations at baseline, dietary initiation, week 6, week 12 and every 3 months thereafter and telephone consultations at weeks 1, 3 and 9. Patients will receive dietary and ketone monitoring education.

Assessments and monitoring undertaken at each consultation include anthropometry, biochemistry, compliance, tolerance, acceptability, quality of life and ketosis.

Informed consent will be obtained prior to enrollment and the patient may withdraw at any time.

An information study is also embedded into KEATING, to aid understanding of the patients' recruitment experience and viewpoints, by interviewing a sub-sample of patients and their relatives/ carers. This will enable the design of bespoke strategies to optimise recruitment to future trials related to ketogenic diets and gliomas


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date March 5, 2019
Est. primary completion date March 5, 2019
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Age =16 years

- Patient at The Walton Centre NHS Foundation Trust

- Performance status =2

- Confirmed histological diagnosis of glioblastoma

- Undergone surgical resection or biopsy and will go onto receive/ is receiving/ has received oncological treatments

Exclusion Criteria:

- Having prior use of KD

- Kidney dysfunction

- Liver dysfunction

- Gall bladder dysfunction

- Metabolic disorder

- Eating disorder

- Diabetes (requiring medication)

- Body mass index = 18.5kg/m2

- Weight loss medications

- Currently pregnant or breast feeding

- Performance status =3

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MKD
Modified ketogenic diet
MCT
Medium chain triglyceride ketogenic diet

Locations

Country Name City State
United Kingdom Univeristy of Liverpool/ The Walton Centre NHS Foundation Trust Liverpool Merseyside

Sponsors (3)

Lead Sponsor Collaborator
University of Liverpool Vitaflo International, Ltd, Walton Centre NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess retention and drop out rates Number of patients who start randomized treatment as a proportion of the number randomized ; 12 weeks
Primary To assess retention and drop out rates The number of patients who complete 12 weeks as a proportion of the number randomized 12 weeks
Primary To assess retention and drop out rates Description of barriers and facilitators to data collection and participant retention 12 weeks
Primary To assess retention and drop out rates The time to dietary discontinuation 12 weeks
Secondary Estimation of recruitment rates Actual recruitment compared to proposed recruitment 12 months
Secondary Enrollment of patients Number of patients initiated on diet prior to starting oncological treatments. 12 months
Secondary Enrollment of patients Number of patients initiated on diet during oncological treatments. 12 months
Secondary Enrollment of patients Number of patients initiated on diet post oncological treatments. 12 months
Secondary Long term retention Time to dietary discontinuation after week 12 2 years
Secondary Dietary adjustments required to achieve ketosis Number of dietary adjustments to macronutrient composition of MCT and MKD diets required to achieve ketosis. 2 years
Secondary Self reported dietary compliance Self reported by compliance rate 2 years
Secondary Calculated dietary compliance Analysed by comparing macronutrient content assessed via 3 day food diaries to advised macronutrient content. 2 years
Secondary MCT compliance Dose of MCT taken compared to dose advised. 2 years
Secondary Ketosis levels Self reported urinary ketone levels twice daily for first 6 weeks then once per week thereafter and blood ketone and glucose levels weekly. 2 years
Secondary Dietetic time required for interventions Dietetic time spent on clinical and non clinical activities relating to the trial. 2 years
Secondary Protocol refinements required Number of deviations from the protocol including reasons for deviations. 2 years
Secondary Sample size estimates for future trials Number of participants required for future phase III clinical trials 2 years
Secondary Quality of life Change in quality of life assessed through EORTC QLQ C30 and BN 20 questionnaires 2 years
Secondary Food acceptability Change in food acceptability assessed through food acceptability questionnaire 2 years
Secondary Gastrointestinal side effects Number of reported gastrointestinal side effects assessed through EORTC QLQ C30 questionnaire and Common Terminology Criteria for Adverse Events. 2 years
Secondary Changes to biochemical markers Changes to biochemical markers (renal, bone, LFT, lipid profiles) during the duration of the diet. 2 years
Secondary Anthropometric changes Changes to anthropometry (weight, body mass index, fat mass, muscle circumference, hand grip strength) during the duration of the diet. 2 years
Secondary Completeness of data Number of complete data sets for all trial outcomes 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Terminated NCT02905643 - Discerning Pseudoprogression vs True Tumor Growth in GBMs